Prognostic usefulness of clinical features and pretreatment 18F-FDG PET/CT metabolic parameters in patients with angiosarcoma

Donghe Chen; Mengmeng Tang; Sha Lv; Huatao Wang; Wendi Du; Xin Zhao; Lili Lin; Yunqi Zhu; Guangfa Wang; Huanyan Zhu; Kui Zhao

doi:10.21037/qims-21-563

Prognostic usefulness of clinical features and pretreatment ¹⁸F-FDG PET/CT metabolic parameters in patients with angiosarcoma

Quant Imaging Med Surg. 2022 May;12(5):2792-2804. doi: 10.21037/qims-21-563.

Authors

Donghe Chen¹, Mengmeng Tang², Sha Lv³, Huatao Wang¹, Wendi Du¹, Xin Zhao¹, Lili Lin¹, Yunqi Zhu¹, Guangfa Wang¹, Huanyan Zhu¹, Kui Zhao¹

Affiliations

¹ PET Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
² Department of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
³ State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China.

Abstract

Background: To investigate the prognostic value of clinical features and metabolic parameters in pretreatment ¹⁸F-2-fluoro-2-deoxy-D-glucose (¹⁸F-FDG) positron emission tomography/X-ray computed tomography (PET/CT) scans of patients with angiosarcoma, a rare neoplasm that has not been well characterized.

Methods: In this retrospective study, 19 patients with a histopathologically confirmed diagnosis of angiosarcoma who had undergone pretreatment ¹⁸F-FDG PET/CT scans were enrolled. We recorded the age at presentation, sex, underlying diseases, sites of primary tumors, Karnofsky Performance Status (KPS) score, Eastern Cooperative Oncology Group (ECOG) score, time from onset to diagnosis, laboratory examinations, sites and sizes of primary tumors, treatment modalities, histologic features and American Joint Committee on Cancer (AJCC) stage, maximum standardized uptake value (SUVmax), average SUV (SUVavg), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) of primary tumors and the whole body. Univariate and multivariate survival analyses for overall survival were performed according to the metabolic parameters and other clinical variables.

Results: Patients ranged in age from 27 to 79 years (median: 59 years) with different angiosarcoma types covering all tumor grades and subtypes. Seven (7/19) patients had anemia of varying degrees of severity. Lymph node metastases (n=10) and/or distant metastases (n=11) of angiosarcoma were common. Bone or bone marrow (10/19) and lung (8/19) were the most common distant metastatic organs. Patients with bone metastases, low hemoglobin levels and high ferritin levels had significantly poorer overall survival than those with non-bone metastases, normal hemoglobin levels and normal ferritin levels by the log-rank test, with P values of 0.027, 0.030 and 0.015, respectively. Patients with multiple organ metastases had significantly poorer overall survival than those with single organ metastasis (log-rank P=0.008). In multivariate survival analysis, only whole-body metabolic tumor volume using SUV_max cut-off value of 2.5 (wMTV_2.5) was a significant independent prognostic factor. For wMTV_2.5, 870.3 cm³ was the best cut-off point to discriminate between a good and poor prognosis (log-rank P=0.01).

Conclusions: The systemic ¹⁸F-FDG PET/CT with high sensitivity and specificity has significant advantages in the evaluation of angiosarcoma, particularly in detecting occult metastases. Bone metastases on ¹⁸F-FDG PET/CT, low hemoglobin levels and high ferritin levels were all associated with a poorer prognosis. MTV_2.5 of the whole body is a significant independent metabolic prognostic factor for overall survival in patients with angiosarcoma.

Keywords: Angiosarcoma; clinical features; fluoro-2-deoxy-D-glucose (FDG); metabolic parameters; metabolic tumor volume; positron emission tomography/X-ray computed tomography (PET/CT); prognosis; total lesion glycolysis (TLG).